FOGHORN THERAPEUTICS
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
FOGHORN THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.foghorntx.com
Total Employee:
51+
Status:
Active
Contact:
617-586-3100
Email Addresses:
[email protected]
Total Funding:
111 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Sitelinks Search Box Euro Microsoft Exchange Online
Similar Organizations
EPIX Therapeutics
EPIX Therapeutics develops and commercializes microwave radiometry-based products for electrophysiology tests.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Ally Therapeutics
Ally Therapeutics solves the immune response barriers for gene therapy.
Ambrx
Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
BeneVir Biopharm
Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bioline AgroSciences
Bioline produces and markets a wide range of invertebrate biological control organisms which are used for control of insect pests.
Bionaut Labs
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality.
CDx Diagnostics
CDx Diagnostics develops and provides diagnostic systems intended to prevent cancer by detecting pre-cancerous cells.
FoxBio
FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Ginkgo Bioworks
Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.
HotSpot Therapeutics
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Iconic Therapeutics
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.
ImCheck Therapeutics
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
LNC Therapeutics
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases.
Metabolic Solutions Development
Metabolic Solutions Development develops innovative therapeutics based on a novel pharmacological method to treat type two diabetes.
Nereid Therapeutics
Nereid Therapeutics is discovering new disease treatments by applying research and technologies in biomolecular condensates.
OncoHealth
OncoHealth designs screening devices that detects and diagnoses cancer.
Tenaya Therapeutics
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.
Tissue Genesis
Tissue Genesis is an innovator of advanced tissue engineering and cell therapy solutions.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Irving Investors
Irving Investors investment in Venture Round - Foghorn Therapeutics
Invus
Invus investment in Venture Round - Foghorn Therapeutics
Casdin Capital
Casdin Capital investment in Venture Round - Foghorn Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Venture Round - Foghorn Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-10 | Foghorn Therapeutics Announces Chief Scientific Officer Succession |
Official Site Inspections
http://www.foghorntx.com Semrush global rank: 4.12 M Semrush visits lastest month: 2.93 K
Unable to get host informations!!!
More informations about "Foghorn Therapeutics"
Leadership - foghorntx.com
Murphy Hentemann, PHD, joined Foghorn in 2018 as head of program management, now VP, program leadership. He brings more than 18 years of drug discovery experience to the …See details»
Work Here - foghorntx.com
Collaborate to innovate “This is the same boat everybody is in. It's hard. There's a reason it’s hard. And we're at the forefront of doing this work.”See details»
Foghorn Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 617-586-3100 Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this …See details»
Foghorn Therapeutics Company Profile | Management and
SQL International Organization for Standardization . C# Microsoft . Python Python Software Foundation . Other Communication and Collaboration Software (4 Technologies) ...See details»
Foghorn Therapeutics Inc. Company Overview, Contact Details ...
May 20, 2024 Foghorn Therapeutics Inc. Biotechnology Research Massachusetts, United States 51-200 Employees. Foghorn Therapeutics is pioneering the discovery and development of a …See details»
Documents & Charters | Foghorn Therapeutics
The Board of Directors of Foghorn Therapeutics Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
Foghorn Therapeutics Inc. (FHTX) - Yahoo Finance
See the company profile for Foghorn Therapeutics Inc. (FHTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Foghorn Therapeutics Announces Chief Scientific Officer Succession
Jan 10, 2022 Dr. Carl Decicco commented, “It has been a privilege to serve as Foghorn’s Chief Scientific Officer for the past three years. I am proud of the broad and deep pipeline that we …See details»
Investor FAQs - Foghorn Therapeutics
Please contact [email protected] at Foghorn Therapeutics for any additional Investor inquiries. How can I view documents Foghorn filed with the Securities & Exchange …See details»
Foghorn Therapeutics - Overview, News & Similar companies
Jul 19, 2024 Foghorn Therapeutics contact info: Phone number: (617) 586-3100 Website: foghorntx.com What does Foghorn Therapeutics do? Foghorn Therapeutics Inc., a clinical …See details»
Kevin Wilson, PHD - foghorntx.com
Kevin Wilson joined Foghorn in 2019 as director in medicinal chemistry and now serves as VP, Head of Chemistry. He brings more than 20 years of drug discovery experience to the …See details»
Foghorn Therapeutics to Participate in Three Upcoming Investor …
Nov 12, 2024 Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn. Contact: Karin Hellsvik, Foghorn Therapeutics …See details»
Dan Dinu, MBA - foghorntx.com
He brings more than 20 years of experience to the organization and leads strategy, architecture, and governance of the IT group. Prior to joining Foghorn, Dan worked as a management …See details»
Foghorn Code of Conduct (2019-03-12) - Foghorn Therapeutics
Foghorn is committed to fostering a culture within Foghorn’s organization in which breaches of compliance are not acceptable. In conjunction with this Code-of-Conduct Program (the …See details»
Murphy Hentemann, PHD - foghorntx.com
Murphy Hentemann, PHD, joined Foghorn in 2018 as head of program management, now VP, program leadership. He brings more than 18 years of drug discovery experience to the …See details»
Presentations | Foghorn Therapeutics
Dec 4, 2020 The Investor Relations website contains information about Foghorn Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Foghorn Therapeutics to Participate in Three Upcoming
Nov 12, 2024 Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn. Contact: Karin Hellsvik, Foghorn Therapeutics …See details»
Foghorn Therapeutics Announces Participation in Upcoming …
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines …See details»
Science - foghorntx.com
The chromatin regulatory system enables and orchestrates the first step of gene expression, accessing DNA by unpacking chromatin. Gene expression requires a series of steps, in which …See details»